CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


QuestionnaireWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (11)


Name (Synonyms) Correlation
drug87 Anti-SARS-CoV2 Serology Wiki 0.32
drug1524 bidirectional oxygenation mouthpiece Wiki 0.32
drug6 0.9%NaCl Wiki 0.32
drug1043 Plaquenil 200Mg Tablet Wiki 0.32
drug405 Data collection up to 1 year Wiki 0.32
drug761 Lopinavir/ritonavir 400 mg/100 mg Wiki 0.32
drug606 Hydroxychloroquine Pre-Exposure Prophylaxis Wiki 0.32
drug144 BCG Vaccine Wiki 0.18
drug591 Hydroxychloroquine Wiki 0.07
drug1035 Placebo oral tablet Wiki 0.06
drug1016 Placebo Wiki 0.05

Correlated MeSH Terms (15)


Name (Synonyms) Correlation
D007246 Infertility NIH 0.32
D012170 Retinal Vein Occlusion NIH 0.32
D005157 Facial Pain NIH 0.32
D008268 Macular Degeneration NIH 0.32
D008269 Macular Edema NIH 0.32
D007153 Immunologic Deficiency Syndromes NIH 0.18
D045169 Severe Acute Respiratory Syndrome NIH 0.11
D004630 Emergencies NIH 0.11
D018352 Coronavirus Infections NIH 0.09
D007239 Infection NIH 0.08
D003141 Communicable Diseases NIH 0.06
D055371 Acute Lung Injury NIH 0.04
D012127 Respiratory Distress Syndrome, Newborn NIH 0.04
D012128 Respiratory Distress Syndrome, Adult NIH 0.03
D011014 Pneumonia NIH 0.02

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0000789 Infertility HPO 0.32
HP:0011505 Cystoid macular edema HPO 0.32
HP:0012636 Retinal vein occlusion HPO 0.32
HP:0002721 Immunodeficiency HPO 0.18
HP:0002090 Pneumonia HPO 0.02

There are 10 clinical trials

Clinical Trials


1 Descriptive Study Regarding the Ambulant Screening Protocol for COVID-19 in Times of High SARS CoV-2 Prevalence

Descriptive prospective study to investigate the prevalence of COVID 19 during ambulant screening

NCT04334252 COVID 19 Other: Questionnaire

Primary Outcomes

Description: Prevalence of fever, cough, anorexia, fatigue, diarrhea, vomiting, dyspnee, sore throat and sputum

Measure: Prevalence of symptoms

Time: at the ambulant screening

Description: Prevalence of positive COVID 19 tests in patients planned for surgery, treatment or investigation in the hospital

Measure: Prevalence of positive Sars CoV-2 PCR

Time: at the ambulant screening

Description: Prevalence of positive radiological findings in CT scans of the lungs of planned for surgery, treatment or investigation in the hospital

Measure: Prevalence of positive radiological findings

Time: at the ambulant screening

Secondary Outcomes

Description: Prediction of symptoms of COVID 19, based on evaluated baseline questionnaire

Measure: Prediction of symptoms

Time: 2 weeks after surgery or treatment

Description: Prediction of symptoms of COVID 19, based on radiological findings of CT scans

Measure: Prediction of symptoms

Time: 2 weeks after surgery or treatment

Description: Prediction of symptoms of COVID 19, based on COVID 19 PCR results

Measure: Prediction of symptoms

Time: 2 weeks after surgery or treatment

2 Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period

The outbreak linked to SARS-CoV-2 infection was declared a Public Health Emergency of International Concern on 30 January 2020. In all of the emergency Departments, a major reorganization was necessary, notably with the creation of a specific channel for COVID-19 suspect patients. Thus, all caregivers involved must adapt day by day to new places of exercise, new protocols,...The major influx of patients, the precautions to be taken, the specifics of the pathology and its management have profoundly changed daily practice. This exogenous hospital tension impacts all caregivers and more particularly their resilience capacities. Resilience is defined as an ability to recover from or adjust easily to misfortune or change. The Resi-CoV study aims to assess the level of resilience of caregivers of different specialties and trades in the context of covid-19.

NCT04349163 Psychological Other: Questionnaire

Primary Outcomes

Description: CD-RISC-25 : Connor-Davidson Resilience Scale - 25. This scale contain 25 questions each range from 1 to 5. The total is 100 points which means a very high level of resilience.

Measure: compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.

Time: 14 days

3 Evaluation of the Management of Dental Emergencies During COVID 19 Crisis

"For 12 years, the odontology service of the Pitié-Salpêtrière hospital group (GHPS) has been responsible for day and night dental emergency care. Several surveys have been conducted in order to analyze the sociological characteristics of the patients and the typology of the acts performed. These studies indicate that pain is the main reason for consultations, cited by 60 to 80% of patients. So far, very few studies have been done in the context of emergencies. Very recently, a study was undertaken on the satisfaction of patients consulting the odontological emergencies of the GHPS, during a thesis work. This study, carried out in collaboration with the URC Pitié Salpêtrière, under analysis, relates to the satisfaction of patients consulting the odontological emergencies of the GHPS during the day and week, Monday to Friday, excluding night and week emergencies -end (WE). An additional study (URGDENT-NW) aiming at completing this study by focusing on patients consulting the emergency room at night and during the weekend is also in progress. The COVID19 Crisis changed the organization and the venue of patients at the emergency dental service. Therefore this project, based on the same protocol as URGENT and URGDENT-WE, aims at evaluating the Odontology Emergency Reception Service (SAUO) during the COVID 19 epidemy. It will be carried out in the form of a survey whose objective is to assess: on the one hand, the effectiveness of the care provided in this emergency functional unit, and on the other hand the satisfaction of the patients after their passage to the emergency room ."

NCT04354272 Orofacial Pain Orofacial Edema Dental Trauma Oral Infection Other: Questionnaire
MeSH:Emergencies Facial Pain

Primary Outcomes

Description: "Self report measure of pain on the numeric scale 24h after the visit "

Measure: Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable

Time: Day 1

Secondary Outcomes

Description: the pain is measured with the numeric scale

Measure: Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable

Time: Day 3 and Day 7

Description: Perception of welcoming, waiting time will be measured with a 0-10 numeric scale

Measure: welcoming quality from hospital staff

Time: Day 1

Description: The patient anxiety will be measured by numeric scale at Day 0, Day 1, Day 3, Day 7

Measure: anxiety score

Time: Day 0, Day 1, Day 3, Day 7

Description: The perception is measured just after care with a 0-10 numeric scale

Measure: perception of the technical quality of the emergency treatment

Time: Day 1

4 Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers

This original study will assess the impact of the coronavirus health crisis on the management of patients undergoing medical treatment for cancer, in particularly on the modification of the hospital organization. It will also provide a record of the progress of patients who will have been treated during the epidemic period and infected by the virus. We will also assess the psychological impact of the pandemic in patients but also in caregivers

NCT04366154 COVID-19 Cancer Other: Questionnaire
MeSH:Communicable Diseases Infection

Primary Outcomes

Description: Proportion of patients with modification of the treatments administered

Measure: To assess the impact of the COVID-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy

Time: up to 6 months

Description: Proportion of patients with change in the rate of treatment administration

Measure: To assess the impact of the COVID-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy

Time: up to 6 months

Description: Proportion of patients with change in the number of cures administered

Measure: To assess the impact of the COVID-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy

Time: up to 6 months

Description: Proportion of patients with change of modality of administration (home administration to replace day hospital administration, teleconsultation uses)

Measure: To assess the impact of the COVID-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy

Time: up to 6 months

Secondary Outcomes

Description: Score of questionnaires of Perceived Stress Scale [0-40 points]

Measure: Evaluate the perceived stress on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of Impact of Event Scale-Revised [0-88 points]

Measure: Evaluate the post-traumatic stress on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of sleep disorders (ISI scale, 0-28 points)

Measure: Evaluate the sleep disorders on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of quality of life (FACT-G scale)

Measure: Evaluate the quality of life on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of cognitive complaints (Fact-Cog scales; 0-148 points)

Measure: Evaluate the cognitive complaints on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of Perceived Stress Scale [0-40 points]

Measure: Evaluate the perceived stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)

Time: up to 3 months

Description: Score of questionnaires of Impact of Event Scale-Revised [0-88 points]

Measure: Evaluate the post-traumatic stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)

Time: up to 3 months

Description: Score of questionnaires of burnout ((Maslach Burn Out Inventory scale, 0-132 points)

Measure: Evaluate the burnout on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)

Time: up to 3 months

Description: Score of questionnaires of feeling of personal effectiveness (0-30 points)

Measure: Evaluate the feeling of personal effectiveness on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)

Time: up to 3 months

5 Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.

A weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. Possible symptoms of COVID19 are asked for and use of healthcare services and testing for COVID19. Weekly reports are being send to the national institutions to update advice given to this group.

NCT04382508 Immune Suppression Immune Deficiency Infection COVID Children, Adult Other: Questionnaire
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Immunologic Deficiency Syndromes
HPO:Immunodeficiency

Primary Outcomes

Description: To describe frequency of cough, fever, diarrhoea, shortness of breath, sore throat, blocked nose, red eyes, headache, joint pain, muscle pain, fatigue, chills, nausea, vomiting, diarrhoea over a year

Measure: To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting

Time: 1 year

Secondary Outcomes

Description: Patient/parent reported positive tests for COVID19

Measure: Number of children/adults tested positive for COVID19

Time: 1 year

Description: Patient/parent reported admissions in hospital because of COVID19

Measure: Number of children/adults admitted in hospital because of COVID19

Time: 1 year

Description: Patient/parent reported effect of COVID19 on daily activities

Measure: To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children

Time: 1 year

6 Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019 (COVID-19) Infections: a Case-control Study

It has been suggested that ibuprofen might be associated with more severe cases of coronavirus infections, based on the observation that severe COVID cases had been exposed to ibuprofen, resulting in a warning by the French authorities. This was attributed to: 1. a suggestion that ibuprofen might upregulate ACE-2 thereby increasing the entrance of COVID-19 into the cells, 2. an analogy with bacterial soft-tissue infections where more severe infections on NSAIDs are attributed to an immune-depressive action of NSAIDs, or to belated treatment because of initial symptom suppression, 3. fever is a natural response to viral infection, and reduces virus activity: antipyretic activity might reduce natural defenses against viruses. However fever reduction in critically ill patients had no effect on survival. However, these assertions are unclear: upregulation of ACEII would increase the risk of infection, not necessarily its severity, and would only apply to the use of NSAIDs before the infection, i.e. chronic exposure. It would be irrelevant to the infection once the patients are infected, i.e., to symptomatic treatment of COVID-19 infection. Anti-inflammatory effect masking the early symptoms of bacterial infections resulting in later antibiotic or other treatment is not applicable: there is no treatment of the virus that might be affected by masking symptoms. Antipyretic effect increasing the risk or the severity of infection would apply equally to all antipyretic agents including paracetamol, which share the same mechanism of action for fever reduction. EMA remains prudent about this assertion In addition, excess reliance on paracetamol while discouraging the use of ibuprofen might increase the risk of hepatic injury from paracetamol overdose. Paracetamol is the prime drug associated with liver injury and transplantation, in voluntary and inadvertent overdose or even at normal doses. This might be increased by COVID-related liver function alterations. It is therefore proposed to conduct a case-control study in a cohort of patients admitted to hospital in France with COVID-19 infection.

NCT04383899 Coronavirus Infection Other: Questionnaire
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Describe medications including ibuprofen used prior to admission associated with worse infection in COVID-19 patients in France. Thanks to a questionnaire created for the study, with 5 questions on existing pathology, drugs administrated symptom onset and when, hospitalisation. Each questions have a multiple choice.

Measure: Describe medications used prior to admission associated with worse infection in COVID-19 patients in France.

Time: At inclusion day

Description: Quantify medications including ibuprofen used prior to admission associated with worse infection in COVID-19 patients in France. Thanks to a questionnaire created for the study, with 5 questions: existing pathology, drugs administrated symptoms onset and when, hospitalisation. Each questions have a multiple choice.

Measure: Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France.

Time: At inclusion day

Secondary Outcomes

Description: Describe patient characteristics thanks to the same questionnaire.

Measure: Describe other patient characteristics with worse infection in COVID-19 patients in France.

Time: At inclusion day

Description: Quantify patient characteristics thanks to the same questionnaire.

Measure: Quantify other patient characteristics with worse infection in COVID-19 patients in France.

Time: At inclusion day

7 Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff

Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.

NCT04387838 Sars-CoV2 Diagnostic Test: Anti-SARS-CoV2 Serology Other: Questionnaire

Primary Outcomes

Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.

Time: From Day 0 to Day 60

Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.

Time: From Day 0 to Day 30

Description: Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.

Time: From Day 30 to Day 60

Secondary Outcomes

Description: Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.

Measure: Anti-SARS-Cov2 seroprevalence at Day 0.

Time: Day 0

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and sex

Measure: Correlation between seroconversion and socio-demographic factors - sex

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and age

Measure: Correlation between seroconversion and socio-demographic factors - age

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.)

Measure: Correlation between seroconversion and professional factors - job type

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type

Measure: Correlation between seroconversion and professional factors - personal protective equipment type

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals

Measure: Correlation between seroconversion and non-professional factors - contact with infected individuals

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment

Measure: Correlation between seroconversion and non-professional factors - wearing of professional equipment

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures

Measure: Correlation between seroconversion and non-professional factors - respect of barrier gestures

Time: Day 60

8 Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents

In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.

NCT04395859 Age Related Macular Degeneration Diabetic Macular Edema Retinal Vein Occlusion Procedure: Questionnaire Other: Data collection up to 1 year
MeSH:Macular Degeneration Macular Edema Retinal Vein Occlusion
HPO:Cystoid macular edema Macular edema Retinal vein occlusion

Primary Outcomes

Description: Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up

Measure: Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic

Time: Baseline (Before confinement) and 6 months after resumption of follow-up

9 Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic

The COVID-19 pandemic brought new challenges to our nationwide healthcare system, with rapid escalation of the number of affected individuals over a handful of weeks. From March 13, a first set of measures was taken to minimise the spread of the virus, which largely impacted societal and economical daily life. A view days later, on March 17, the country was put in "lockdown" and all non-urgent medical treatments were cancelled or postponed. As recommended by the major scientific fertility societies, all non-ivf fertility treatments were discontinued abruptly, whereas started ivf stimulations were continued until oocyte aspiration, where after a freeze-all strategy was applied. There is little information available for women aiming for pregnancy or embarking on assisted conception. Given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially attenuate risk may be required, which will inevitably impact patients wellbeing and overall success rates. A questionnaire was developed to explore patients perspectives on different aspects of their fertility treatment during the COVID-19 pandemic. The questionnaire contains the following sections: - demographic variables; - questions regarding the fertility history of the respondent; - questions regarding the impact of fertility treatment cancellation / postponing fertility treatment during COVID-19 on their life, psychological wellbeing and relationship; - questions regarding continuing medical treatment on their own, or seeking treatment elsewhere; - questions regarding the satisfaction of measures taken by their fertility center regarding the COVID-19 pandemic; - questions regarding expectations of further treatments, with focus on safety issues related to the COVID-19 pandemic. Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.

NCT04396210 Coronavirus COVID ART Fertility Issues Other: Questionnaire
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Measure: Patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

Measure: Patients reproductive behaviour by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

Measure: Patients views on resuming fertility treatment by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

10 Psychological Impact of the Health Measures Generated by the SarsCov-2 Pandemic in Adolescents (COVADO)

The lockdown of the French population is a health measure put in place in response to the pandemic linked to a new coronavirus, SARS-CoV-2 (Covid-19). After a health campaign to recommend hygienic "barrier gestures" and social distancing, the decision to confine the population at the national level was decided by the executive from Monday 16 March to Monday 11 May 2020. The national confinement implies the restriction of movement to the strict necessary, outings near the home and the closure of schools and communities. These decisions have led to an unprecedented state of stress for the entire French population, the consequences of which are unknown in the short, medium or long term. The objectives of this study are to evaluate the psychological impact of the confinement on adolescents with or without chronic disease and also the difficulties and fears engendered by deconfinement .

NCT04406558 Psychological Adaptation Psychology, Social Other: Questionnaire

Primary Outcomes

Description: Scale 0-21

Measure: Anxiety score from the Generalized Anxiety Disorder 7 (GAD-7) questionnaire

Time: At inclusion

Secondary Outcomes

Description: Scale 0-60

Measure: Depression score from the Adolescent Depression Rating Scale (ADRS) questionnaire

Time: At inclusion

Description: 8 items that are scored on a four-point scale and 3 sub scales: intrusion (4 items); avoidance (4 items) and arousal (5 items)

Measure: Post traumatic score questionnaire: Children's Revised Impact of Events Scales -CRIES13

Time: At inclusion

Description: a question on the quality and quantity of sleep will be asked to the teenager on a questionnaire

Measure: Presence or absence of difficulty in falling asleep, sleeping

Time: At inclusion

Description: a question on the presence or absence of feeding difficulty will be asked to the teenager on a questionnaire

Measure: Presence or absence of feeding difficulty

Time: At inclusion

Description: a question on the presence or absence of difficulty performing physical activity will be asked to the teenager on a questionnaire

Measure: Presence or absence of difficulty performing physical activity

Time: At inclusion

Description: a question on the presence or absence of toxic consomption will be asked to the teenager on a questionnaire

Measure: Presence or absence of toxic consomption (drug, acohol) during the lockdown

Time: At inclusion

Measure: Mean duration time in front of screen (hours per day)

Time: At inclusion

Description: A question on the presence or absence of difficulties with social interactions will be asked to the teenager on a questionnaire

Measure: Presence or absence of difficulties with social interactions

Time: At inclusion

Description: Presence or absence of difficulties with familial interactions

Measure: Presence or absence of difficulties with familial interactions

Time: At inclusion


Related HPO nodes (Using clinical trials)


HP:0002721: Immunodeficiency
Genes 267
WHCR EPG5 CTPS1 MBTPS2 TLR3 IL2RG ISG15 CHD1 CLCA4 JAK3 PRKCD AK2 CD40LG FOXN1 NFE2L2 ATRX TNFRSF1B SKIV2L IFNGR1 TTC37 DCLRE1C TBCE BCR ZBTB24 CD3G BSCL2 SDHD XRCC4 LAMTOR2 IKZF1 AGPAT2 CTBP1 LRRC8A RAG2 ANTXR2 SLC46A1 CHD7 TINF2 CR2 IRF7 USP8 CD3E CD3D IL12B TNFRSF13C NHEJ1 IL2RG CD79B TNFSF12 EPG5 CUL4B ICOS LAT MAGT1 IL7R TBX1 TERT UNC93B1 LCK DCLRE1C MTHFD1 HIRA NSD2 CARD9 IRF8 UROS SHANK3 PIK3CD UFD1 NHP2 MYC CD81 CD79A TNFSF12 UNC119 RAG1 LRBA NCF2 LMNB2 BUB1B SEC23B FGFRL1 LYST CDCA7 BLNK RMRP FOS TCF3 RAG1 RBCK1 NFKB2 SIN3A CTLA4 JMJD1C CD81 MEIS2 PGM3 POLE IKBKG ADA IRF8 STAT1 PARN CFTR TNFRSF13C IL21R TNFRSF13B ICOS NFKB1 LIG4 CD28 SIK3 USB1 RAG1 IKBKG ADA DNMT3B RAG2 CR2 STX1A SEC24C SDHC ADA2 BTK IL2RG NCF1 FOXN1 TNFRSF13C LAMTOR2 ACTB SP110 RTEL1 SKIV2L PIK3R1 CDC42 RTEL1 CARD11 DNMT3B SDHB CDH23 HELLS PRKDC PIK3CA TYK2 AP3D1 TRAF3 FRAS1 CORO1A SPATA5 DOCK2 AKT1 RTEL1 XIAP FCGR3A TFRC ACD COMT ACP5 LETM1 RNF168 CD19 PNP POLE CHD1 RMRP AGL STAT1 ARVCF NFKB2 SH2D1A WAS NFKB1 IL21 AK2 IL2RA CDC42 GATA1 PARN ZBTB24 SMARCAL1 STIM1 TNFRSF13B NPM1 COG6 DKC1 CYBA MALT1 MS4A1 ICOS PTEN DCTN4 TINF2 DKC1 LIG4 TBX1 CR2 PRPS1 RAG1 UNG CAV1 HYOU1 RAC2 LYST IRAK4 RAB27A TNFRSF4 TGFB1 FCN3 USF3 HBB CCDC47 IFNGR2 RREB1 IRAK4 IKBKG CD19 CAVIN1 RAG2 PPARG AICDA IKBKB CD40 PGM3 PKP1 KLLN MYD88 CPLX1 EXTL3 MMUT XIAP STAT1 ORAI1 IKBKG CD19 CD247 TBK1 CYBB PIK3R1 TICAM1 CTC1 WRAP53 GP1BB TTC7A TTC7A NOP10 RNF168 BCL10 MAPK1 WIPF1 MS4A1 IL12RB1 TERC DKC1 BCL11B XRCC4 IGHM STK4 IL7R PTPRC IGLL1 CRKL IL2RB ATM IRF2BP2 GATA2 SPATA5 TERT
SNP 0